Asunto(s)
Edema/etiología , Dermatosis de la Pierna , Infecciones Estreptocócicas , Anciano , Quimioterapia Combinada , Eritema/etiología , Femenino , Fiebre/etiología , Heparina/uso terapéutico , Humanos , Dermatosis de la Pierna/etiología , Penicilina G/uso terapéutico , Infecciones Estreptocócicas/diagnóstico , Infecciones Estreptocócicas/tratamiento farmacológico , Streptococcus pyogenesRESUMEN
The frequency of non soil dwelling anaerobic infections is increasing. The authors report 33 cases of Bacteroides fragilis bacteremias, and study the responsabilities of different factors of prognosis (especially age and underlying conditions). Nitroimidazoles are very active against all Bacteroides fragilis. This therapy is the drug of choice for such infections.
Asunto(s)
Infecciones por Bacteroides/complicaciones , Sepsis/etiología , Adulto , Factores de Edad , Anciano , Infecciones por Bacteroides/tratamiento farmacológico , Bacteroides fragilis , Femenino , Humanos , Masculino , Persona de Mediana Edad , Nitroimidazoles/uso terapéutico , Sepsis/tratamiento farmacológicoRESUMEN
Four rates of rifampicin infusion ranging from 3.3 to 15 mg/min in 12 tuberculous patients were studied. Blood samples (n = 10) were drawn during infusion and 8 h later. Urine samples were collected in six fractions during a 24-h period. Rifampicin and desacetylrifampicin were measured by high-pressure liquid chromatography. Results show that the maximum plasma concentrations increase linearly for each dose with the rate of infusion, and that the amounts excreted in the urines are highly dependent on the administered dose. Simulation of plasma concentrations after different dosage regimens shows that a double rate of infusion--20 mg min-1 during 1 h and then 200 mg h-1--allows plasma concentrations to be quickly reached and maintained at a 20 mg L-1 level, far higher than the minimum inhibitory concentrations of most germs.
Asunto(s)
Rifampin/análogos & derivados , Rifampin/metabolismo , Tuberculosis Pulmonar/metabolismo , Adulto , Anciano , Femenino , Semivida , Humanos , Infusiones Parenterales , Cinética , Masculino , Persona de Mediana Edad , Rifampin/administración & dosificaciónRESUMEN
The authors review 27 cases of cervical tuberculosis in the adult, complete and homogeneous and essentially describe their experience concerning positive diagnostic factors as well as their therapeutic approach. Considering the results obtained, they favour early surgical treatment ranging from simple adenectomy to complete and conservative cellulo-lympho-adenectomy which is the essential treatment of choice in multi-nodal forms. This surgical attitude makes possible to considerably shorten the duration of the local course by eliminating recurrences but on the essential condition that it is accompanied by prolonged medical treatment consisting of a triple association of major anti-tuberculous drugs.
Asunto(s)
Tuberculosis Ganglionar/cirugía , Adolescente , Adulto , Anciano , Femenino , Humanos , Ganglios Linfáticos/cirugía , Masculino , Persona de Mediana Edad , Tuberculosis Ganglionar/diagnóstico , Tuberculosis Ganglionar/tratamiento farmacológico , Tuberculosis Ganglionar/patologíaRESUMEN
The authors have carried during one year, in the hospital of Villeneuve-Saint-Georges, a prospective study on 229 cases of pneumococcal infections with bacteriological findings. They emphazise the frequency, the high-exposed groups and the gravity of these infections despite of the antibiotherapy. The emergence of multiply resistant pneumococcus makes out another argument for proposing a preventive vaccination taking notice of the most frequent serotypes found in France.
Asunto(s)
Infecciones Neumocócicas/epidemiología , Adolescente , Adulto , Anciano , Antibacterianos/uso terapéutico , Niño , Preescolar , Farmacorresistencia Microbiana , Femenino , Francia , Hospitales Generales , Humanos , Inmunoterapia , Lactante , Recién Nacido , Masculino , Persona de Mediana Edad , Infecciones Neumocócicas/prevención & control , Estudios Prospectivos , SerotipificaciónRESUMEN
Cefotiam (SCE 963), a new, broad-spectrum, third generation cephalosporin was used in the treatment of 136 patients suffering from respiratory tract infections, urinary tract infections, septicemia, meningitis, biliary tract infections and osteoarthritis infections. Cefotiam was administered in monotherapy to 98 patients at the mean posology of two grams per day (extreme doses: 1 to 6 g). The following clinical effectiveness was noted: 83 successes and 18 failures on 101 available clinical reports. The general, biological tolerance and renal tolerance was good in all patients.